Photo taken from Erman Akkus/X
Feb 21, 2024, 18:13
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Tremelimumab plus durvalumab (STRIDE) in HCC:
HIMALAYA update
- 1171 patients, first line, STRIDE or Durva or sorafenib
- STRIDE versus sorafenib, OS: HR 0.78 (0.67-0.92
- durvalumab versus sorafenib, OS: HR 0.86 (0.74-1.01)
- long-term OS benefit of STRIDE versus sorafenib
- Durvalumab maintained OS noninferiority to sorafenib.”
Proceed to the article.
Source: Erman Akkus/X